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According to the classification scheme ofLancefield (1), strains ofStreptococcus
agalactiae were found to belong to group B streptococci (GBS).` Although Fry
and Eng (2) were the first to describe three fatal group B postpartum infections
and to point out the clinical importance of GBS in human infections, it was not
until 1973 that GBS were firmly established as a major cause in perinatal
infections (3-8). Meanwhile a wealth of information has been accumulated and
has been summarized in a number ofreview articles (9-11).
GBS have been isolated with increasing frequency from infants with early- and
late-onset septicemia and meningitis (5, 12), but they also contributed to more
infrequent infections in adults such as abortion, abscesses, bacteremia, impetigo,
arthritis, septicemia, and urinary tract infections (2, 5, 8, 13-20).
Besides the common group antigen, most strains ofGBS share an extracellular
protein first described in 1944 by Christie, Atkins, and Munch-Petersen, which
accordingly was named CAMP factor (21). The CAMP factor causes lysis ofred
blood cells that contain at least 45 mol - % ofsphingomyelin (22) and which have
been exposed to Staphylococcus aureus #-toxin (sphingomyelinase). Since the
designation CAMP factor neither describes the hemolytic activity nor its biolog-
ical properties of Ig binding (recorded in this paper), we will use the name
protein B for this extracellular substance of group B streptococci.
Used in the past to rapidly identify GBS by the CAMP reaction (23-26),
protein B has been characterized asa polypeptide withMr of 15,000 (27); 23,500
(28); 33,000 (29); and 25,000 (30). Part ofthe mechanism ofthe CAMP reaction
was described by Doery et al. (31), Bernheimer et al. (28), and by work from our
laboratory (32).
Besides the demonstration of mouse protective antibodies against group B
streptococci (33), protein B-inactivating antibodies were also shown in human
and animal sera (29), indicating that protein B is an antigen and is produced
during the course of infection. However, the protein B-induced lysis of target
cells in vitro remained rather an epiphenomenon and was not considered to be
ofrelevance in vivo. Hence, the protein B has yetnotbeen investigated in respect
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￿
GBS, group B streptococci; PAP, peroxidase antiperoxidase;
PA, protein A; SLO, streptolysin O.
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to its possible role in pathogenicity using chemically defined preparations. Thus,
the work presented here provides the first evidence in a mouse infectious disease
model that protein B, possibly by binding to the Fc site ofa variety ofmammalian
Igs of the G and M classes, causes rapid septicemia with fatal outcome in mice
infected with sublethal doses of GBS.
Material and Methods
Protein B Production.
￿
GBS Type IIb (NCTC 8181) was obtained from Central Public
Health Laboratory, London, United Kingdom. Organisms were cultured on sheep agar
plates incubated at 37 ° C for 20-24 h in a 5% C02 atmosphere. Fermenter cultivation of
group B streptococci was performed in trypticase peptone broth (No. 11921 ; Becton
Dickinson & Co., Mountain View, CA) as reported earlier (34).
Purification ofProtein B.
￿
Protein B was purified to homogeneity from the ammonium
sulfate-precipitated culture supernatant, as previously reported (30), by ultrafiltration,
hydrophobic interaction chromatography, and chromatofocusing.
Determination of Hemolytic Activity of Protein B.
￿
Activity was measured by the kinetic
test as described (34). 1 U of protein B is defined as that amount of protein that causes
change in absorbance at a = 546 nm of AA = 0.1/min at 30°C.
RadiolabelingofProteinB.
￿
The method of Rosa et al. (35) was used for radioiodination.
The protein B (0.4 mg; sp act, 1 .3 X 105 U/mg) was dissolved in 0.8 ml of PBS and kept
at 4°C in a platinum vial required for electrolytic labeling. To this solution 20 A1 of
Na115I, 2 mCi (Amersham International, Buckinghamshire, United Kingdom) were added.
Electrolysis was performed at 1 .8 V/20 gA for 20 min using the equipment of Gerhard,
G.m.b.H., Bonn, Federal Republic of Germany. Iodination usually resulted in a protein
B preparation of 0.5-1 ACi/Ag protein.
Determination ofProtein.
￿
Protein was measured according to Peterson (36), with BSA
as a standard.
Inactivation of Hemolytic Activity of Protein B by Ig.
￿
Hemolytic activity was determined
using the kinetic assay as described (34). The interaction of Ig with protein B was detected
by inhibition of the CAMP reaction after incubation with individual Ig fractions. The test
was performed at 30°C in 1 .5 ml cuvettes containing 1 .4 ml of 0.01 M Tris-HCI, 0.145
M NaCl, 0 .01 M MgC12, pH 7.4, and 10 Al of sphingomyelinase (E.C. 3.1 .4.12 .) treated
SRBC. Lysis was started by the addition of 0.125 gg of protein B in 50 A1 of buffer or
with the same amount of protein B preincubated for 5 min at room temperature with
50-100 ug of the individual Ig fractions, respectively.
Reagents.
￿
Human, rabbit, and bovine IgG and mouse IgM were purchased from Sigma
Chemical Co., St. Louis, MO; human IgM mAbs were obtained from Behringwerke AG,
Marburg, Federal Republic of Germany. Human myeloma IgM-Fc5 fragments (chromat-
ographically pure) were obtained from Jackson Immuno Research Laboratories, Avon-
dale, PA. The monoclonal IgGI and IgG2a subclasses (mouse) were a generous gift from
Professor C. Sorg, Munster, Federal Republic of Germany . IgGI, clone 25179, possessed
anti-macrophage specificity; IgG2, clone 910137, had anti-HLA-DR specificity.
Site ofBinding.
￿
The CAMP reaction was also used to investigate the site of protein B
binding to Ig. Individual IgG (100 t+g/20 Al) and IgM (200 Ag/20 A1) antibodies were
incubated before the addition of protein B with 800 Ag/40 Eel partially purified protein A
(PA) (Sigma Chemical Co.) for 5 min at 20°C. Protein B (0.250,ug in 40 Al of 0.01 M
Tris-HCI buffer, 0 .145 molar in NaCl, pH 7.4) was then added to the solution, which was
again incubated (5 min, 20 °C) before starting lysis with 50 AI of this mixture.
The ability of the protein B/Ig complex to recognize Fab-specific antigenic binding
sites was tested in a second type of experiment. Since antibodies against streptolysin O
(SLO) inhibit SLO-induced lysis of SRBC (37), this system seemed suitable to detect
whether or not protein B-complexed anti-SLO antibodies retained their capacity to
inhibit SLO-induced hemolysis. The kinetic assay used for hemolytic activity of protein B
measurement (see above) was used, but with the modification that SRBC were not
sensitized with sphingomyelinase, which constitutes an essential step in the CAMP reaction722
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(21, 31). SLO was purified as reported earlier (38) and kept lyophilized at -80°C until
use. SLO (3 mg/ml; SA, 2,400 HU/mg) was dissolved in 0.01 M Tris/HCl buffer, pH
7.4, containing 0.145 M NaCl and 0.01 M cystein. Complete lysis of the test erythrocytes
was obtained with 50,1 (36 HU) of SLO. This amount of SLO was neutralized by 5,U] of
an anti-SLO immune serum (rabbit) with an anti-SLO titer of 1 :32.
Protein B and the anti-SLO serum were mixed at a ratio of 2:1 (vol/vol). Based on the
binding ratio of protein B/IgG of 1 :70, a 20-fold excess ofprotein B over the total amount
of Ig in the antiserum was used.
Gel Exclusion Chromatography.
￿
Sephadex G-150 SF (Pharmacia Fine Chemicals, Upps-
ala, Sweden) was swollen in PBS, transferred to a C 16/40 column (Pharmacia Fine
Chemicals), and equilibrated with the same buffer. ' 2'I-p protein B (-40,000 cpm/kg) or
"'I-protein B/Ig complexes prepared by incubation of 's I-protein B (1 ug) with individ-
ual Ig species (200-400 wg in 50 til of PBS, for 10 min at 20 ° C) were chromatographed
at a flow rate of 8 ml/h at 8 ° C) . Fractions of 2.4 ml were collected and analyzed for
protein and radioactivity in the Autogamma Scintillation Spectrometer (Packard Instru-
ment Co., Inc., Downers Grove, IL). Protein values were not corrected for the small
amount <<-1 tzg of "'I-protein B present in "'I-protein B/Ig complexes.
Affinity Chromatography. Chromatographically pure human IgM- and IgG-agarose
(capacity, I mg protein/I ml gel ; Jackson Immuno Research Laboratories) were used for
affinity chromatography. For IgM, 2 ml, and for IgG, 5 ml of gel were packed into two
separate columns (C 10/20, Pharmacia Fine Chemicals), each of which was equilibrated
with 300 ml of PBS. Thereafter, 50 ug (200 Al) of purified protein B, trace labeled with
"'I-protein B (100,000 cpm; specific radioactivity 2.5 X 105 cpm/,Ug) in PBS, were applied
to each of the columns. Protein B was then adsorbed to the corresponding Ig-agarose at
a flow rate of 7 ml/h at 8 ° C. Both the columns were thoroughly washed until no protein
or radioactivity was detectable in the eluate. The protein B that bound to either the
immobilized IgM or IgG was then eluted stepwise from the respective column with 50 ml
(1%) of Triton X-100 in PBS and subsequently with 50 ml of 6 M guanidine-HCI in 0 .1
M glycine-HCI, pH 3.0. Fractions of 2.4 ml were collected and analyzed for protein and
radioactivity.
Antigen and Immunization.
￿
To produce antibodies, I mg of purified protein B (SA,
1 .3 X 105 U/mg) in 1 ml CFA (Difco Laboratories Inc., Detroit, MI) was injected
subcutaneously into rabbits at multiple sites. Booster injections were given at weeks 5 and
6, and the production of antibodies was followed by the Ouchterlony technique. Blood
was drawn from the animal's ear usually 6 d after the last injection.
Streptococcal Strains.
￿
GBS types la and Ib used for animal inoculation were kindly
supplied by Dr.Jiri Rotta, Institute of Hygiene and Epidemiology, Prague, Czechoslovakia.
The strain NCTC-8181 also used for protein B production (kindly typed by Dr. Rotta)
was type IIb.
Mice.
￿
Male NMRI-mice, 4-6 wk old (30-33 g) used for experimental infections with
GBS were obtained from the Zentrale Versuchstieranstalt, Hannover, Federal Republic
of Germany.
Mouse Passage.
￿
GBS Types la, Ib, and IIb were grown in 300-ml Erlenmeyer flasks
containing 100 ml of trypticase peptone broth (Becton Dickinson & Co., Mountain View,
CA) with 1% yeast extract (Difco Laboratories Inc.) in a 5% C02 atmosphere at 37 °C.
Cells were harvested by centrifugation (4,000 rpm, 4°C, 10 min) and washed twice in
PBS. The pellet was resuspended in PBS to give an ODsoo of 10.0, corresponding to 2 X
109 CFU/ml. The mouse was infected intraperitoneally with 500,ul (109 CFU) and killed
after 6-7 h (types la, Ib) or 14-16 h (type IIb) when the animal was moribund. Liver and
spleen were removed aseptically, homogenized together in 2.5 ml of PBS, and the number
of organisms was determined by spreading 0.1 ml of serial 10-fold dilutions of the
homogenate on blood agar plates. The homogenate was used to infect animals in 28
repeated passages to increase the virulence of the strain (33). Finally, 10 animals were
inoculated at the same time, killed, and the organs were processed as mentioned above
and pooled to prepare a large volume of tissue homogenate. Aliquots of 1 .0 ml of the
homogenate with 2-5 X 108 CFU were kept at -80°C until used for animal inoculation.JURGENS ET AL.
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TABLE I
Inhibition ofProtein B Hemolytic Activity by Immunoglobulins
Effect of Protein B in Experimental Infection.
￿
The mouse infectious disease model
described above was used to demonstrate the influence of protein B on experimental GBS
infection. Four groups of animals (A-D) were formed. Animals of groups A-C were
infected intraperitoneally with a sublethal dose of 104 CFU in 200 JAI tissue homogenate
for types la and Ib, and with 10' CFU in 200 ul for type IIb. Animals of group B were,
in addition, injected in the tail vein with 30 ul of sterile filtered protein B in PBS (115
ug; SA, 1 .1 X 105 U/mg) at 0, 1 .5, 3, 4.5, 6, 7 .5, and 9 h after infection. The total amount
of protein B was 0 .8 mg. As an appropriate control, group C animals received in parallel
the same volume (7 X30 ul) of PBS intravenously. Group D animals not infected received
0.8 mg of native protein B at corresponding intervals. It should be noted that type la and
Ib were very sensitive to storage in diluted buffer as well as to freezing and thawing.
Therefore, the appropriate dilutions were made immediately before use and the number
of organisms injected was controlled each time.
Detection ofProtein B in Tissue Sections ofInfected Mice.
￿
The PAP method (39) was used
to detect protein B in tissue sections of mice infected intraperitoneally with a lethal dose
of the GBS-containing tissue homogenate (10' CFU). The reagents, swine-anti-rabbit
globulin and the PAP complex were both obtained from Dakopatts G.m.b.H., Hamburg,
Federal Republic of Germany. 3-Amino-9-ethylcarbazole (4 mg in N,N-dimeth-
ylformamide) was used as a peroxidase substrate. Tissue sections (3-5 um thick) were
prepared by freeze fractioning of tissue blocks of liver or spleen. Before the addition of
the PAP complex, tissue sections were incubated with antibodies derived from a rabbit
that had been immunized with purified protein B, as described (see above).
Results
Interaction of Protein B with Ig.
￿
Besides the specific binding of antibodies to
protein B (29) by antigenic determinants we observed recently that antibodies of
the IgG and IgM classes inhibited the CAMP reaction in vitro although the
presence of protein B-specific antibodies was unlikely. To investigate this inter-
action in more detail, protein B was incubated with the Ig fractions listed in
Table 1 . It was found that all the IgG and IgM antibodies tested and derived
from different mammalian species inhibited the protein B-induced lysis of SRBC .
Interestingly, the CAMP reaction was also blocked by one monoclonal IgM
(human) and two monoclonal IgG antibodies (mouse) lacking protein B deter-
minant specificity. The amount of Ig needed to inhibit the CAMP reaction
differed for IgG and IgM . The inhibitory molar ratio of protein B to IgM was
found to be 1 :20, and 1 :70 for IgG .
Species Ig class or
subclass Specificity Inhibition
Human IgM Monoclonal +
IgG Polyclonal +
Mouse IgM Polyclonal +
IgGI Monoclonal +
IgG2a Monoclonal +
Rabbit IgG Polyclonal +
Bovine IgG Polyclonal +724 BINDING OF CAMP FACTOR TO IMMUNOGLOBULINS
0 x 60
n
J 50
O7
C 60
d
do --^ -moo a,
10 20 30
￿
10 20 30
FRACTION NUMBER
￿
FRACTION NUMBER
FIGURE 1 . Characterization of "I-labeled protein B/Ig complexes by gel exclusion chro-
matography on Sephadex G-150. Thecurves show (A) theelution behavior of "'I-protein B
(cpm) in the absence (0) and in the presence (p) of human IgM mAbs. (40) IgM (jug protein
per fraction) in the complex. (B) Coelution of IgM-Fc5N fragments (*; wg protein/fraction)
with "'I-protein B (0; cpm) is depicted.
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FIGURE 2.
￿
Demonstrationof protein B bindingto IgG and IgMagarose by affinity chroma-
tography. (A) (O) elution of protein B (wg protein/fraction) from IgG agarose with (a) 1%
Triton X-100 and (b) guanidine/HCI (6 M). (B) Curves show the same elution pattern after
desorption of protein Bfrom IgM agarose with Triton X-100 (a) and guanidine/HCI (b). See
A.
Furthermore, the hydrodynamic properties of the protein B/Ig complexes
were studied by gel exclusion chromatography on Sephadex G-150. Thus, the
elution profiles of the 1251-protein B/IgM (human monoclonal) and "'I-protein
B/IgM-Fc5,, complexes were compared with that of 1251-protein B in the absence
of Ig. It is obvious that both IgM (Fig. 1 A) and IgM-Fc5,, antibody fractions (Fig.
I B) were coeluted with the 1251-protein B (Fig. 1 A and B) with the void volume
(Vo = 27 ml), whereas I25I-protein B alone emerged from the column with an
elution volume of Ve = 58 ml (Fig. 1A). The same elution pattern was seen when
complexes of protein B with the other Ig species listed in Table I were passed
through the column (data not shown) .
The stoichiometry of protein B/IgG or IgM complex formation and the
binding forces between the components were analyzed by column chromatog-
raphy with immobilized human IgG or IgM. When purified protein B was applied
to the IgG-agarose column at a molar ratio of protein B/IgG of 1 :25, complete
adsorption was observed. Protein B was not removed by extensive washings with
PBS but was desorbed to ^-65% of total activity with 1% Triton X-100 in PBS
(Fig. 2A; a). Elution of the residual protein B (35%) was finally achieved by
applying 6 M guanidine-HCI in 0.1 M glycine, pH 3.0 (Fig. 2A ; b). When IgM
agarose was used, protein B was bound to IgMat a molar ratioof 1:1 . Desorption
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TABLE 11
Lysis
* Components in parentheses were incubated together before the addition of protein B or SLO.
with the same eluents resulted in the same elution profile as depicted in Fig. 2B.
The experiments with both IgG- or IgM-agarose indicated that the amount of
protein B bound to immobilized IgG or IgM differed from that found in protein
B/IgG or IgM complexes in aqueous solutions.
Site ofBinding of Protein B to Ig.
￿
The coelution of '251-protein B with IgM-
Fc5 (Fig. 1 B) suggests that protein B may bind in a PA-like way to the Fc sites
of Ig. Since the binding ofIg to protein B can be monitored by the inhibition of
the protein B-induced lysis, it seemed possible to define more precisely the site
of binding of the protein B to the Ig molecule by applying the kinetic test and
using substances competing either for the antigen recognition or Fc site of the
Ig. The first type of interaction was investigated using an anti-streptolysin O
antiserum (rabbit; anti-SLO titer, 1:32) neutralizing the hemolytic activity of
SLO. When protein B was incubated with the anti-SLO serum, protein B-
induced lysis was blocked (Table I1). The protein B/anti-SLO complex, however,
was still capable of binding to SLO, thereby inhibiting streptolysin O-induced
lysis in the hemolysis test (Table II). Protein B was used in this experiment in a
20-fold excess over the precalculated amount of Ig present in the rabbit anti-
serum. The experiment revealed that the Fab site ofanti-SLO antibodies com-
plexed by protein B or PA retained their function to specifically bind their
antigen (SLO), thus inactivating the hemolytic activity ofSLO.
Additionally, PA and protein B were used to compete with each other for the
binding at the Fc site of the Ig molecule or anti-SLO/SLO complex. The
experiment showed that theanti-SLO/SLO complexwas stillable to bind protein
B and to inhibit the CAMP reaction . When PA was incubated with the anti-
SLO/SLO complex or one ofthe Ig species(listedin Table 1) before the addition
of protein B, complete lysis of SRBC by protein B was observed (Table 11).
Appropriate controls indicated that neither PA nor protein B, once fixed to the
Ig molecule, was capable of displacing each other from their binding site. In
addition, protein B and PA were not lytic by themselves in the SLO system
(Table 11).
Protein B in Pathogenicity.
￿
Although there was no evidence from the literature
that protein B was involved in pathogenicity, the unspecific binding of protein B
to IgG or IgM molecules suggested to use that protein B could play a role in
GBS infections.
Our preliminary experiments revealed that mice infected intraperitoneally
with a single dose of GBS, type la and Ib of 10' CFU, exhibited no signs of
illness. Mice inoculated intraperitoneally with 104 CFU became slightly ill but
recovered usually within 2 d. When killed, after this time, liver and spleen were
mostly sterile, whereas animals killed after 24 h still showed a colony count of
Identification ofthe Site ofBinding
CAMP reaction
Protein B + anti-SLO
of
Lysis
-
Protein Bat theImmunoglobulin
SLO reaction
SLO +anti-SLO
Protein B + (anti-SLO/SLOcomplex)* - SLO + (anti-SLO/protein B)
Protein B + (anti-SLO/PA) + SLO + (anti-SLO/PA)726
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TABLE III
Effect ofProtein B in Experimental Infection with GBS Type la
TABLE IV
* p.i., postinfection.
Slightly ill: rough fur, weak hyperventilation, reduced activity.
§Severely ill: rough fur, strong hyperventilation, stupor, closed and/or glued eyes.
Effect ofProtein B in Experimental Infectionwith GBS Type Ib
* Slightly ill: rough fur; weak hyperventilation, reduced activity.
$Severely ill: rough fur; strong hyperventilation; stupor; closed and/or glued eyes.
102-105 CFU/ml in the homogenate of spleen and liver (Tables III and IV;
group A) . The blood of these animals was sterile at this stage of infection.
However, when mice were treated over a period of 9 h with seven successive
injections in the tail vein of 30 A1 each of purified protein B (total, 210 jl = 0.8
mg) together with a sublethal dose ofGBS (intraperitoneally), theanimalsbecame
severely ill and occasionally died. Colony counts of the homogenate of liver and
spleen of these animals after 24 h were between 107 and 108 CFU/ml, and the
same number of organisms was found in 1 ml blood (Tables III and IV; group
B). Mice treated with the same sequence of intravenous injections of protein B
but not infected with GBS remained healthy (Tables III and IV; group D). This
was also true for GBS-infected animals receiving seven repeated intravenous
injections (7 X 30 al) of PBS as a control. The blood of these animals was sterile,
although colony counts in the tissue homogenate amounted to 108-105/ml
(Tables III and IV; group C). Animals receiving a sublethal dose of GBS only
(Tables III and IV; group A) showed the same colony counts and recovered
usually within 2 d. Mice were also infected according to the before-mentioned
protocol with GBS type IIb (NCTC 8181). In contrast to type la and Ib, the
lethal dose was found to be 108 CFU, although the strain has been passaged 28
times. The sublethal dose was determined to be 107 CFU. The effect of protein
B on mice infected with type IIb (data not shown) was the same as documented
for animals infected with type la and Ib.
Infec- CFU in liver
Num- tious andspleen CFU in
Group Mice treated with: berof dose Signsof illness homog- blood/ml
animals (CFU) enate/ml (24 h p.i.)
(24 h p.i.)*
A GBS 9 104 Slightly ill* 0-105 0-101
B GBS + protein B 11 104 Severely ill§ 107-108 107-108
C GBS + PBS 10 104 Slightly ill* 0-105 0-101
D Protein B 8 - Healthy Sterile Sterile
Infec- CFU in liver
Num- tious andspleen CFU in
Group Mice treated with: berof dose Signsof illness homog- blood/ml
animals (CFU) enate/ml (24 h p.i.)
(24hp.i.)
A GBS 12 104 Slightly ill* 0-105 0-108
B GBS + protein B 8 104 Severely ill$ 107-108 107-108
C GBS + PBS 8 104 Slightly ill* 0-105 0-101
D Protein B 8 - Healthy Sterile SterileJORGENS ET AL .
FIGURE 3 .
￿
Detection of protein B in tissue sections of the liver of a mouse infected with
GBS . Tissue sections (3-5 Am) prepared by freeze sectioning were incubated with rabbit
antibodies against purified protein B and stained subsequently by the PAP method . Masses of
protein B-producing cocci are visible in and outside of macrophages . Individual cocci differ
greatly in their behavior to stain with peroxidase . Magnification, x 1,500.
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Detection of Protein B in Tissue Sections .
￿
Since the protein B used in this study
was produced by fermenter cultivation in artificial medium it seemed important
to also demonstrate its in vivo production by GBSin theinfected animal, although
it has been shown earlier (29) that animals responded to GBS infections by
elevated antibody titers against protein B . When tissue sections after freeze
sectioning were incubated with anti-protein B antibodies (rabbit) and subse-
quently stained using the PAP method, clusters of protein B-producing cocci
were seen in and outside of macrophages . Fig . 3 shows a section of the liver of
an infected mouse in which numerous macrophages with engulfed GBS are seen .
The intensity of staining differs considerably for individual cocci, showing some
with a strong and others with a weaker peroxidase reaction .
The same histologic pattern was seen after incubation of tissue sections with
an anti-protein B antibody (rabbit) before fluorescence staining with an anti-
rabbit FITC conjugate . Furthermore, fluorescence staining revealed that anti-
genic material was found not only on the surface of cocci but was also found as
halo shapes around clusters ofcocci outsideof themacrophages(data not shown) .
Discussion
Surface components with the capacity to bind in a nonimmune reaction to the
Fc part of the Ig have been described for S. aureus (protein A) and streptococci728
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of different serogroups (40-43). With the exception of PA, these Fc receptors
on bacterial cell surfaces have not been defined in respect to their chemical
nature. In contrast, the protein B of group B streptococci represents a well-
defined polypeptide of known physicochemical properties (24-26, 28-32, 44)
that is released from the organisms during the mid- to postlogarithmic phase of
growth into the medium as a soluble extracellular protein ofstrongly amphiphilic
properties (32, 34). In addition, we have been able to show that protein B is also
produced in vivo during the course ofexperimental GBS infection (Fig. 3). The
protein B that may be compared with the soluble fraction of PA can bind IgG
and IgM Ig in a nonimmune reaction at the Fc site of the Ig molecules. Besides
the binding of Ig of the -G and -M classes from a variety of mammalian species
(Table I). Protein B was found to combine also with IgG subclasses and with
both monoclonal and polyclonal IgG and -M globulins. In contrast to the
properties of the Fc receptors found on bacterial cell surfaces of S. aureus and
group A, C, G, and U streptococci (40-43), protein B was able to bind to the
IgM-Fc5, fragment of human myeloma protein (Fig. 1), thereby blocking the
CAMP reaction (Table II).
The binding forces active in protein B/Ig complex formation did:not differ
considerably for either IgG or IgM when studied by affinity chromatography
with immobilized Ig (Fig. 2). However, the dissociation behavior of the protein
B/Ig complex in the presence of Triton X-100 or guanidine-HCI in affinity
chromatography (Fig. 2) suggests that two different complexes with different
dissociation constants exist under given conditions. Moreover, it should be
mentioned that an additional type of protein B/Ig complex is formed by the
interaction of protein B with specific antibodies (29), which exhibit true deter-
minant specificities for the protein B. Preliminary experiments indicated that an
immunoprecipitate is obtained in agar gel diffusion using purified protein B and
antibodies raised against purified protein B in the rabbit. No such precipitates
were visible when protein B was complexed in agar gel with Ig fractions lacking
protein B specificity.
In fluid phase complexes the ratio of IgG or IgM to protein B was estimated
to be 1:70 and 1:20, respectively. It was thus conceivable that relatively small
amounts of protein B released in systemic infections could effectively impair the
immune response of the host. It was found that mice infected intraperitoneally
with a sublethal dose of GBS and that received in parallel seven repeated
intravenousinjections ofpurified protein B developed a severe septicemia within
24 h after infection. The presence of GBS in the blood drawn from the heart of
infected animals after 24 h was documented by positive blood cultures in which
108 CFU/ml were found. Animals that developed a severe GBS infection usually
harbored up to 10'-108 CFU in the combined liver and spleen tissue homog-
enate. When tissue sectionsofliver or spleen ofinfected animalswere investigated
after 15 h using the PAP method (39), large numbers ofcocci were found, the
majority of which were spread onto the capsular surface of the organs . Few
microabscesses were found at this stage ofsepticemia, although numerous clusters
of macrophages with phagocytized cocci were seen (Fig. 3). It was found unex-
pectedly that not only soluble extracellular protein B (mol wt 25,000)was stained
outside of the cocci, but that the cocci themselves were stained. The intensity ofJORGENS ET AL.
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staining of individual cocci varied greatly regardless of the staining technique
applied (i.e., peroxidase or FITC). It seemspossible that GBS of different growth
phases exhibit differences in their metabolic activities, which consequently effects
the biosynthesis and/or release of protein B in vivo.
Furthermore, the immunohistological findings suggest that protein B is not
only present extracellularly but also on the surface of GBS, thus exhibiting Ig/Fc
receptor function. The number of receptors exposed on the cell surface may,
however, depend on the growth phase of individual cocci, as stated above. This
aspect couldbe of relevance in discussing the controversial results on the binding
of IgG to group B or D streptococci (40, 41).
Although our data provide strong evidence that protein B is involved in
pathogenicity of GBS infections, care must be taken in extending this view to
infectious disease models other than mouse. Presently, we are far from an
understanding of the sequence of events initiated by the interaction of protein
B with Ig or other factors of the immune system, such as complement (42) or
phagocytosis (45). Further work will be needed to disclose the role of protein B
and the fate of the protein B/Ig complexes, especially in human infections (i.e.,
early- and late-onset septicemia in neonates). This work could profit from the
data presented here on the hitherto unknown properties of protein B.
Summary
The protein B of group B streptococci can bind in a nonimmune reaction to
Ig of the IgG and IgM classes of various mammalian species (i.e., human, mouse,
rabbit, and bovine). Protein B binding involves the Fc parts of both IgG and
IgM molecules. Monoclonal or polyclonal IgGor IgM and the IgM-Fc5 fragment
of human myeloma protein combined with the protein B thereby inhibiting
protein B-induced hemolysis in the CAMP reaction. The protein B/Ig complex
can be dissociated with 1% Triton or guanidine-HCI (6 M). Mice infected
intraperitoneally with sublethal doses of group B streptococci (GBS) and that
received seven repeated intravenous injections of highly purified protein B
during the first 9 h of infection developed fatal septicemia within 24 h with
colony counts of up to 108 CFU/ml in the blood. Animals treated in the same
way with either PBS or trypsinized protein B recovered. The protein B itself was
not pathogenic when injected into healthy mice. Tissue sections of liver or spleen
from mice infected with a lethal dose of GBS revealed the presence of protein B
together with large numbers of cocci when stained by the peroxidase method
using specific antibodies raised against purified protein B in the rabbit.
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